Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrbusNeich Medical Group Holdings's revenue for the
six
months ended in Dec. 2025 was €82.8 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €168.4 Mil.
OrbusNeich Medical Group Holdings's Revenue per Share for the
six
months ended in Dec. 2025 was €0.10.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.20.
During the past 7 years, OrbusNeich Medical Group Holdings's highest 3-Year average Revenue per Share Growth Rate was 20.30% per year. The lowest was -0.60% per year. And the median was 11.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
OrbusNeich Medical Group Holdings Revenue Related Terms
OrbusNeich Medical Group Holdings Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrbusNeich Medical Group Holdings Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where OrbusNeich Medical Group Holdings's Revenue falls into.
OrbusNeich Medical Group Holdings Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €168.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrbusNeich Medical Group Holdings (FRA:Q8T) has a Revenue of €168.4 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on OrbusNeich Medical Group Holdings and its competitors.
Is OrbusNeich Medical Group Holdings' Revenue too high?
OrbusNeich Medical Group Holdings' current Revenue is €168.4 Mil. Overall, OrbusNeich Medical Group Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does OrbusNeich Medical Group Holdings' Revenue compare to ISRG and BDX?
OrbusNeich Medical Group Holdings' Revenue of €168.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on OrbusNeich Medical Group Holdings and its competitors. OrbusNeich Medical Group Holdings's current Revenue is €168.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrbusNeich Medical Group Holdings stock overvalued right now?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a current Revenue of €168.4 Mil. The stock's GF Value™ is €0.48, compared to a current price of €0.37 — trading 22.1% below its estimated fair value. The current Revenue is €168.4 Mil. OrbusNeich Medical Group Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For OrbusNeich Medical Group Holdings (FRA:Q8T), the current Revenue is €168.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrbusNeich Medical Group Holdings (FRA:Q8T) Overvalued in 2026?
Based on GuruFocus' analysis, OrbusNeich Medical Group Holdings stock appears to be undervalued.
The current stock price of €0.37 is trading 22.1% below its estimated GF Value™ of €0.48.
Key valuation signals for FRA:Q8T:
Revenue: €168.4 Mil
GF Value™: €0.48 vs. price of €0.37 (22.1% below fair value)
No single metric tells the full story. See the FRA:Q8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrbusNeich Medical Group Holdings Ltd is an investment holding company. The Company principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The group has only one operating segment. The company has presence in APAC, EMEA, Japan, United States, The PRC, and Others of which majority of revenue comes from APAC.
95GF Score
Get the complete analysis for FRA:Q8T
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q8T has been successfully added to your 
